Ningbo MedicalSystem Biotechnology Co Ltd Net Assets
Ningbo MedicalSystem Biotechnology Co Ltd net assets. Based on the latest financial reports, Ningbo MedicalSystem Biotechnology Co Ltd (300439) has net assets worth CN¥2.95 Billion CNY (≈ $431.46 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.66 Billion ≈ $534.88 Million USD) and total liabilities (CN¥706.76 Million ≈ $103.42 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Ningbo MedicalSystem Biotechnology Co Lt to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.95 Billion |
| % of Total Assets | 80.66% |
| Annual Growth Rate | 28.65% |
| 5-Year Change | 73.89% |
| 10-Year Change | 127.85% |
| Growth Volatility | 57.24 |
Net Assets of Ningbo MedicalSystem Biotechnology Co Ltd (2011–2024)
Net assets of Ningbo MedicalSystem Biotechnology Co Ltd from 2011 to 2024. This chart illustrates how Ningbo MedicalSystem Biotechnology Co Ltd's net assets have evolved over time, based on quarterly financial data. See how leveraged is Ningbo MedicalSystem Biotechnology Co Lt's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for Ningbo MedicalSystem Biotechnology Co Ltd (2011–2024)
The table below shows the annual net assets of Ningbo MedicalSystem Biotechnology Co Ltd from 2011 to 2024. For live market cap and overall valuation, see market value of Ningbo MedicalSystem Biotechnology Co Lt.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.93 Billion ≈ $429.26 Million |
+8.38% |
| 2023-12-31 | CN¥2.71 Billion ≈ $396.07 Million |
+7.43% |
| 2022-12-31 | CN¥2.52 Billion ≈ $368.67 Million |
+5.38% |
| 2021-12-31 | CN¥2.39 Billion ≈ $349.84 Million |
+41.72% |
| 2020-12-31 | CN¥1.69 Billion ≈ $246.86 Million |
+21.51% |
| 2019-12-31 | CN¥1.39 Billion ≈ $203.16 Million |
-38.84% |
| 2018-12-31 | CN¥2.27 Billion ≈ $332.15 Million |
-0.74% |
| 2017-12-31 | CN¥2.29 Billion ≈ $334.63 Million |
+25.08% |
| 2016-12-31 | CN¥1.83 Billion ≈ $267.53 Million |
+42.01% |
| 2015-12-31 | CN¥1.29 Billion ≈ $188.39 Million |
+210.13% |
| 2014-12-31 | CN¥415.13 Million ≈ $60.75 Million |
+34.64% |
| 2013-12-31 | CN¥308.32 Million ≈ $45.12 Million |
+52.20% |
| 2012-12-31 | CN¥202.58 Million ≈ $29.64 Million |
+82.76% |
| 2011-12-31 | CN¥110.84 Million ≈ $16.22 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ningbo MedicalSystem Biotechnology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5278.4% over the analyzed period, indicating profitable operations and earnings retention.
Ningbo MedicalSystem Biotechnology Co Ltd Net Assets Breakdown (December 2024)
Ningbo MedicalSystem Biotechnology Co Ltd net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.32 Billion | 45.03% |
| Common Stock | CN¥383.95 Million | 13.06% |
| Other Comprehensive Income | CN¥173.34 Million | 5.90% |
| Other Components | CN¥1.06 Billion | 36.02% |
| Total Equity | CN¥2.94 Billion | 100.00% |
Ningbo MedicalSystem Biotechnology Co Ltd Competitors by Market Cap
The table below lists competitors of Ningbo MedicalSystem Biotechnology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Changzhou Zhongying Science & Technology Co. Ltd
SHE:300936
|
$533.81 Million |
|
China Railway Harbin Group of Technology Corp. A
SHG:688459
|
$533.82 Million |
|
Luyan Pharma Co Ltd
SHE:002788
|
$533.84 Million |
|
AB Sagax (publ)
ST:SAGA-D
|
$533.91 Million |
|
National Petroleum Co Ltd
TW:9937
|
$533.56 Million |
|
Fuchun Technology Co Ltd
SHE:300299
|
$533.35 Million |
|
Tivoli A/S
CO:TIV
|
$533.07 Million |
|
Tibet Weixinkang Medicine Co Ltd
SHG:603676
|
$532.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ningbo MedicalSystem Biotechnology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,714,933,902 to 2,939,828,873, a change of 224,894,971 (8.3%).
- Net income of 257,997,230 contributed positively to equity growth.
- Dividend payments of 52,473,757 reduced retained earnings.
- Other comprehensive income increased equity by 202,474,841.
- Other factors decreased equity by 183,103,343.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥258.00 Million | +8.78% |
| Dividends Paid | CN¥52.47 Million | -1.78% |
| Other Comprehensive Income | CN¥202.47 Million | +6.89% |
| Other Changes | CN¥-183.10 Million | -6.23% |
| Total Change | CN¥- | 8.28% |
Book Value vs Market Value Analysis
This analysis compares Ningbo MedicalSystem Biotechnology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.24x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 21.74x to 1.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.44 | CN¥9.49 | x |
| 2012-12-31 | CN¥0.79 | CN¥9.49 | x |
| 2013-12-31 | CN¥1.20 | CN¥9.49 | x |
| 2014-12-31 | CN¥1.62 | CN¥9.49 | x |
| 2015-12-31 | CN¥4.15 | CN¥9.49 | x |
| 2016-12-31 | CN¥4.73 | CN¥9.49 | x |
| 2017-12-31 | CN¥5.44 | CN¥9.49 | x |
| 2018-12-31 | CN¥5.43 | CN¥9.49 | x |
| 2019-12-31 | CN¥3.89 | CN¥9.49 | x |
| 2020-12-31 | CN¥4.77 | CN¥9.49 | x |
| 2021-12-31 | CN¥6.28 | CN¥9.49 | x |
| 2022-12-31 | CN¥6.55 | CN¥9.49 | x |
| 2023-12-31 | CN¥7.09 | CN¥9.49 | x |
| 2024-12-31 | CN¥7.63 | CN¥9.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ningbo MedicalSystem Biotechnology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.78%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.81%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.26x
- Recent ROE (8.78%) is below the historical average (15.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 48.11% | 27.70% | 1.07x | 1.62x | CN¥42.24 Million |
| 2012 | 45.28% | 27.99% | 0.99x | 1.64x | CN¥71.48 Million |
| 2013 | 33.82% | 23.96% | 0.92x | 1.54x | CN¥72.92 Million |
| 2014 | 33.27% | 23.03% | 0.96x | 1.50x | CN¥96.30 Million |
| 2015 | 12.52% | 23.61% | 0.47x | 1.12x | CN¥32.47 Million |
| 2016 | 10.80% | 16.48% | 0.31x | 2.12x | CN¥12.95 Million |
| 2017 | 12.14% | 8.89% | 0.60x | 2.26x | CN¥40.43 Million |
| 2018 | 12.89% | 7.69% | 0.68x | 2.46x | CN¥54.14 Million |
| 2019 | -43.12% | -18.40% | 0.84x | 2.80x | CN¥-710.35 Million |
| 2020 | 18.24% | 13.01% | 0.71x | 1.98x | CN¥135.31 Million |
| 2021 | 7.65% | 7.97% | 0.63x | 1.53x | CN¥-55.21 Million |
| 2022 | 7.91% | 7.98% | 0.69x | 1.43x | CN¥-52.48 Million |
| 2023 | 9.45% | 13.60% | 0.54x | 1.29x | CN¥-14.94 Million |
| 2024 | 8.78% | 14.81% | 0.47x | 1.26x | CN¥-35.99 Million |
Industry Comparison
This section compares Ningbo MedicalSystem Biotechnology Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,587,816,731
- Average return on equity (ROE) among peers: 17.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | CN¥2.95 Billion | 48.11% | 0.24x | $533.70 Million |
| Berry Genomics Co Ltd (000710) | $117.69 Million | -11.05% | 3.24x | $476.45 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.85 Billion |
| Hangzhou Tigermed Consulting (300347) | $916.90 Million | 13.69% | 0.48x | $5.36 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $3.27 Billion | 11.90% | 0.41x | $1.07 Billion |
| Maccura Biotechnology Co Ltd (300463) | $2.00 Billion | 12.55% | 0.19x | $794.57 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $1.08 Billion | 10.56% | 0.10x | $542.08 Million |
| BGI Genomics Co Ltd (300676) | $6.03 Billion | 34.69% | 0.88x | $2.26 Billion |
| Amoy Diagnostics Co Ltd (300685) | $247.90 Million | 8.51% | 0.22x | $1.09 Billion |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $130.79 Million | 64.49% | 1.52x | $594.87 Million |
About Ningbo MedicalSystem Biotechnology Co Ltd
Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products in China. It is also involved in the provision of Three-party medical diagnosis services. The company offers automated chemistry analyzers; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; total laboratory automation system; mass… Read more